Background. CDI is a frequent cause of morbidity and mortality in hospitalized patients. Despite advances in rapid CDI testing, there are often delays between the onset of symptoms and receipt of test results. We sought to test the hypothesis that the altered CDI intestinal microbiome has a unique volatile metabolite profile, distinct from the profile of patients with other causes of antibiotic-associated diarrhea, which potentially can be used to identify patients with CDI.
before and after implementation of a two-step algorithm for the diagnosis of CDI. The pre-implementation period was defined between May 8, 2016 and May 7, 2017 , and the post-implementation period was May 8, 2017 to May 7, 2018 . Patients were excluded if they were admitted to a pediatric ward, tested for CDI at an outside facility, or if results were available following discharge. The primary outcome was inpatient days of metronidazole and non-parenteral vancomycin per PCR positive patient. Secondary outcomes included defined daily doses of therapy, proportion of untreated patients, time to resolution of diarrhea, all-cause in-hospital mortality, 30-day recurrence, all-cause 30-day readmission, length of stay, and 30-day CDI-related complications. CDI-related complication was a composite of ICU care, megacolon, ileus, surgical intervention. It was calculated that 242 patients were required to achieve at least 80% power to detect a 30% difference in antibiotic days between pre-and post-implementation of two-step C. difficile testing. Wilcoxon two-sample test was used for continuous data, and χ 2 or Fisher exact test were used for categorical data.
Results. See figures. Conclusion. Incorporation of C. difficile toxin EIA to PCR for the diagnosis of CDI resulted in a significant reduction in non-parenteral vancomycin and metronidazole days of therapy. Patient outcomes were not adversely affected by the addition of toxin EIA. The results suggests that toxin EIA may help differentiate between C. difficile colonization and active infection.
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No reported disclosures. Estimates of the incubation period (time between pathogen transmission and symptom onset) for an infection inform infection control and prevention measures. However, observation of the exact transmission and onset times rarely occurs and "coarse, " or doubly interval-censored, data about these exact times are typically used for estimation. The effect of coarseness on the required number of symptomatic cases and the uncertainty of the estimates is unknown, prompting a simulation study informed by data from an investigation of the incubation period of Clostridioides difficile.
Selecting Testing Frequency for Estimation of Incubation Periods: A Simulation Study Based on
Methods. We simulated incubation period data assuming a log-normal distribution, a true median incubation period of 7 days, and a standard deviation of 1 day for sample sizes of 50 to 300 symptomatic cases. For each sample size, we simulated 1000 datasets and examined the impact of testing frequencies, considering intervals between tests of 0.25 to 2 times the median incubation period (1.75 to 14 days) about both transmission and symptom onset times. With these doubly interval-censored observed values, we fit accelerated failure time models to estimate the median incubation time and its 95% confidence interval (CI). Comparing the coverage of the true median and the widths of the CIs, we summarized simulation results across sample sizes and testing frequencies.
Results. Model results from all combinations of sample sizes and testing frequencies yielded median incubation period CIs close to the target 95% coverage level (Figure 1) . The width of the 95% CI about the median decreased with larger sample sizes and shorter times between tests (Figure 2) . Thus, similar estimates and confidence intervals would be observed from 100 symptomatic cases with a testing frequency of 3.5 days as from 200 symptomatic cases tested every 14 days.
Conclusion. The frequency of testing is a key factor in planning studies to estimate incubation periods for infectious diseases. To achieve a desired degree of certainty in estimation, increased frequency of testing can reduce the number of symptomatic cases required. We showed that simulations can assist in planning natural history studies, and these methods could be extended to include population data (e.g., transmission incidence) and cost constraints.
